ACAD
34.25
+0.21
+0.62%
AEMD
4.76
+0.05
+1.06%
APRI
0.423
+0.038
+9.7403%
ARNA
1.62
+0.05
+3.18%
ATEC
0.2
+0.02
+8.11%
CNAT
2.24
+0.01
+0.45%
CRXM
0.181
+0.002
+1.117%
CYTX
2.96
-0.01
-0.34%
DXCM
63.48
-0.34
-0.53%
GNMK
6.64
+0.08
+1.22%
HALO
9.32
+0.17
+1.86%
ILMN
139.83
-0.68
-0.48%
INNV
0.23
-0.09
-28.04%
INO
10.81
+0.36
+3.44%
ISCO
2.2
0.00
0.00%
ISIS
57.56
0.00
0.00%
LGND
119.3
+1.3
+1.10%
LPTN
0.177
+0.016
+10.2181%
MBVX
0.64
-0.03
-3.76%
MEIP
1.38
+0.03
+2.22%
MNOV
6.6
+0.32
+5.10%
MRTX
16.86
+0.86
+5.38%
MSTX
0.308
+0.008
+2.5000%
NBIX
48.07
+0.18
+0.38%
NUVA
53.22
-0.38
-0.71%
ONCS
1.61
-0.07
-4.17%
ONVO
2.59
+0.04
+1.57%
OREX
0.415
+0.011
+2.6492%
OTIC
13.51
-0.25
-1.82%
QDEL
16.18
+0.12
+0.75%
RCPT
231.96
0.00
0.00%
RGLS
5.7
+0.15
+2.70%
RMD
57.42
-0.2
-0.35%
SPHS
0.92
+0.09
+10.84%
SRNE
6.43
+0.29
+4.72%
TROV
5.15
+0.22
+4.46%
VICL
0.39
+0.03
+8.03%
VOLC
18
0.00
0.00%
ZGNX
9.56
+0.16
+1.70%
ACAD
34.25
+0.21
+0.62%
AEMD
4.76
+0.05
+1.06%
APRI
0.423
+0.038
+9.7403%
ARNA
1.62
+0.05
+3.18%
ATEC
0.2
+0.02
+8.11%
CNAT
2.24
+0.01
+0.45%
CRXM
0.181
+0.002
+1.117%
CYTX
2.96
-0.01
-0.34%
DXCM
63.48
-0.34
-0.53%
GNMK
6.64
+0.08
+1.22%
HALO
9.32
+0.17
+1.86%
ILMN
139.83
-0.68
-0.48%
INNV
0.23
-0.09
-28.04%
INO
10.81
+0.36
+3.44%
ISCO
2.2
0.00
0.00%
ISIS
57.56
0.00
0.00%
LGND
119.3
+1.3
+1.10%
LPTN
0.177
+0.016
+10.2181%
MBVX
0.64
-0.03
-3.76%
MEIP
1.38
+0.03
+2.22%
MNOV
6.6
+0.32
+5.10%
MRTX
16.86
+0.86
+5.38%
MSTX
0.308
+0.008
+2.5000%
NBIX
48.07
+0.18
+0.38%
NUVA
53.22
-0.38
-0.71%
ONCS
1.61
-0.07
-4.17%
ONVO
2.59
+0.04
+1.57%
OREX
0.415
+0.011
+2.6492%
OTIC
13.51
-0.25
-1.82%
QDEL
16.18
+0.12
+0.75%
RCPT
231.96
0.00
0.00%
RGLS
5.7
+0.15
+2.70%
RMD
57.42
-0.2
-0.35%
SPHS
0.92
+0.09
+10.84%
SRNE
6.43
+0.29
+4.72%
TROV
5.15
+0.22
+4.46%
VICL
0.39
+0.03
+8.03%
VOLC
18
0.00
0.00%
ZGNX
9.56
+0.16
+1.70%
Home » Archive by Category

NYSE:PFE

Lpath Granted Two Additional U.S. Patents Related to iSONEP and ASONEP Drug Programs

October 5, 2011 – 5:31 am

SAN DIEGO, CA–(Marketwire – Oct 5, 2011) – Lpath, Inc. (OTCBB: LPTN), the industry leader in lipidomics-based antibody therapeutics, received official notification from the U.S. Patent and Trademark Office (USPTO) that Lpath has been issued two fur…